12.2
용법·용량: 부분 약동학적 매개변수
약동학에서는 완전한 약동학적 프로파일을 확보하지 못하는 경우가 흔합니다. 따라서 동물 또는 인체 연구에서 얻은 포괄적인 약동학적 데이터가 없는 상황에서 적절한 용법·용량을 결정하기 위해 약동학자들은 특정한 가정을 설정해야 합니다. 자주 활용되는 가정 중 하나는 생체이용…
많은 약물의 완전한 약동학 프로필은 종종 알려지지 않았거나 사용할 수 없습니다.
따라서 연구자들은 약물의 안전성, 효능 및 치료 범위에 따라 약동학 데이터 없이 투여 요법을 계산하기 위해 몇 가지 가정을 해야 합니다.
한 가지 일반적인 가정은 생체이용률 F를 1 또는 100%로 설정하는 것입니다.
이를 통해 약물이 완전히 흡수되지 않으면 환자가 과잉 투약이 아닌 과소 투약됩니다.
집단 약동학은 환자의 제한된 혈청 약물 농도 샘플로 평균 환자 집단 특성을 사용합니다.
치료 약물 모니터링에서 인구 약동학의 사용은 컴퓨터 데이터베이스의 가용성과 관찰 데이터 분석을 위한 통계 도구의 개발로 인해 증가했습니다.
View the full transcript and gain access to JoVE Core videos
Q1: Why do researchers set the bioavailability factor to 1 when complete pharmacokinetic data is unavailable?
Setting the bioavailability factor, F, to 1 or 100% ensures that if a drug is not fully absorbed, patients are undermedicated rather than overmedicated. This conservative assumption prioritizes patient safety by erring on the side of caution when complete pharmacokinetic profiles remain unknown or unavailable.
Q2: What factors guide the selection of assumptions for dosage regimen calculations?
Pharmacokineticists select assumptions based on three key factors: the drug's safety profile, its efficacy, and its therapeutic range. These criteria ensure that educated assumptions about bioavailability and other parameters lead to appropriate dosage regimens that balance therapeutic effectiveness with patient protection.
Q3: How does population pharmacokinetics help when individual drug data is incomplete?
Population pharmacokinetics uses average patient population characteristics combined with limited serum drug concentration samples from patients to estimate dosing parameters. This approach has increased in therapeutic drug monitoring due to computerized databases and advanced statistical tools for analyzing observational data.
Q4: What role do computerized databases play in modern dosage regimen development?
Computerized databases enable population pharmacokinetics by storing and organizing large amounts of patient data and serum drug concentration information. Combined with statistical tools for observational data analysis, these databases facilitate the calculation of appropriate dosage regimens without requiring complete individual pharmacokinetic profiles.
Q5: Why is population pharmacokinetics increasingly used in therapeutic drug monitoring?
Population pharmacokinetics has gained prominence in therapeutic drug monitoring because it provides a practical alternative when complete pharmacokinetic profiles are unavailable. The availability of computerized databases and development of statistical tools for observational data analysis make this approach feasible and reliable for clinical practice.
Q6: What happens if a drug's bioavailability assumption is set too high?
If the bioavailability factor is set too high, patients may receive insufficient drug doses, resulting in undermedication and reduced therapeutic effectiveness. This is why researchers conservatively set F to 1 or 100% when complete absorption data is unknown, prioritizing patient safety over potential overmedication risks.
Q7: How do statistical tools support dosage regimen calculations in population pharmacokinetics?
Statistical tools designed for observational data analysis enable pharmacokineticists to extract meaningful pharmacokinetic information from limited serum drug concentration samples across patient populations. These tools help calculate reliable dosage regimens by identifying patterns and relationships in population-level data when individual complete profiles are unavailable.